Literature DB >> 15855356

Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.

Daniel R Kapusta1, Melissa A Burmeister, Girolamo Calo', Remo Guerrini, Helmut B Gottlieb, Velga A Kenigs.   

Abstract

The opioid-like peptide nociceptin/orphanin FQ (N/OFQ) produces marked cardiovascular and renal responses after central or peripheral administration in rats. Due to their ability to behave as full/partial agonists or antagonists in different cellular and tissue assays, the present studies were performed to determine how compounds classified as N/OFQ peptide (NOP) receptor partial agonists ([F/G]N/OFQ(1-13)-NH(2), Ac-RYYRIK-NH(2), and Ac-RYYRWK-NH(2)) affect cardiovascular and renal function in vivo. In conscious Sprague-Dawley rats, intracerebroventricular (i.c.v.) administration of each of the three NOP receptor ligands produced profound cardiovascular (depressor), renal excretory (water diuresis), and renal sympathetic nerve activity (inhibitory) responses that were similar to those produced by i.c.v. injection of the native ligand N/OFQ. In contrast, in other groups of rats, the intravenous (i.v.) bolus injection of these same NOP receptor ligands produced responses unlike N/OFQ; N/OFQ evoked an immediate and profound bradycardia and hypotension with no change in urine output, whereas all purported NOP receptor partial agonists elicited a subtle slow onset hypotension, no change in heart rate, and a marked water diuresis. In other studies, i.v. bolus pretreatment of rats with NOP receptor partial agonists prevented/attenuated the cardiovascular depressor effects produced by a subsequent i.v. bolus N/OFQ challenge without affecting the cardiovascular responses to i.c.v. N/OFQ. Together, these findings demonstrate that in conscious rats, NOP receptor partial agonists produce functionally selective effects on cardiovascular and renal function ranging from full agonist (i.c.v., cardiovascular depressor; i.c.v. and i.v., water diuresis), partial agonist (i.v., submaximal hypotension) to antagonist (i.v., blockade of N/OFQ-evoked bradycardia and hypotension) behavior.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855356     DOI: 10.1124/jpet.104.082768

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception.

Authors:  Lawrence Toll; Taline V Khroyan; Kemal Sonmez; Akihiko Ozawa; Iris Lindberg; Jay P McLaughlin; Shainnel O Eans; Amir A Shahien; Daniel R Kapusta
Journal:  FASEB J       Date:  2011-10-28       Impact factor: 5.191

2.  Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.

Authors:  Steven D Chang; S Wayne Mascarella; Skylar M Spangler; Vsevolod V Gurevich; Hernan A Navarro; F Ivy Carroll; Michael R Bruchas
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

Review 3.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

Review 4.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

5.  Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.

Authors:  Ian B Denys; Juan Gao; Jane C Sutphen; Nurulain T Zaveri; Daniel R Kapusta
Journal:  Br J Pharmacol       Date:  2021-12-12       Impact factor: 8.739

6.  In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Anna Rizzi; Barbara Spagnolo; Richard D Wainford; Carmela Fischetti; Remo Guerrini; Giuliano Marzola; Anna Baldisserotto; Severo Salvadori; Domenico Regoli; Daniel R Kapusta; Girolamo Calo
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

7.  Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.

Authors:  G Delaney; K L Dawe; R Hogan; T Hunjan; J Roper; G Hazell; S J Lolait; A J Fulford
Journal:  J Neuroendocrinol       Date:  2012-12       Impact factor: 3.627

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.